皮膚科学における双特定抗体の使用/適用の進展:レビュー
Ting Zhang1, Yang Liu2, Pei Xiong Liew3
1Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
Frontiers in allergy
|September 5, 2025
まとめ
2つの抗原を同時に結合する双固有の抗体は,治療効果を高め,皮膚疾患の副作用を軽減します. このレビューは,炎症性,腫瘍性,感染症性皮膚疾患の治療におけるその可能性を調査します.
科学分野:
- バイオ医学
- 免疫学
- 皮膚科
背景:
- 二固有の抗体は,2つの異なる抗原を同時に結合する設計されたタンパク質です.
- モノクローナル抗体とは異なり,その二重標的能力は複数の経路を同時に調節することを可能にします.
- この二重標的メカニズムは治療効果を高め,標的外毒性を最小限に抑えます.
研究 の 目的:
- バイスペシフィック抗体の基本的な概念を見直す.
- 様々な皮膚疾患の治療における双特定抗体の潜在的応用を探求する.
- 皮膚科における双極性抗体の現状と将来の見通しについて議論する.
主な方法:
- 双特定抗体技術の文献レビュー
- 臨床前および臨床皮膚科学の研究における二固有の抗体の応用に関する分析
- 炎症性,新生性,感染症性皮膚疾患に対する二固有の抗体に関する現在の研究をまとめました.
主要な成果:
- 二固有の抗体は,皮膚疾患の治療結果を向上させるのに有意な可能性を示しています.
- 腫瘍抗原への治療薬の標的投与は全身の毒性を減少させる.
- 複数の疾患に関連する抗原を同時に標的にすることで, 治療効果の相乗効果が得られます.
結論:
- 双極性抗体は皮膚療法における有望な進歩を表しています.
- 皮膚疾患の治療におけるその可能性を完全に実現するために,さらなる研究と臨床試験が必要である.
- このレビューは,皮膚科学における双特定抗体の将来の研究と臨床適用のための基礎を提供します.
関連する概念動画
Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Hybridoma Technology
15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Confocal Fluorescence Microscopy
14.1K
Confocal microscopy is an advanced microscopic technique. The prime advantage of the confocal microscope over other microscopy techniques is its ability to block the out-of-focus light from the illuminated samples using pinholes. It is widely used with fluorescence optics to obtain high-resolution, sharp contrast images. Unlike optical microscopes, confocal microscopes use a focused beam of light laser to scan the entire sample surface at different z-planes. These microscopes are, therefore,...
14.1K
Cross-reactivity
31.5K
Overview
31.5K


